Search

Your search keyword '"Lyon, Rebecca"' showing total 45 results
Start Over Author "Lyon, Rebecca"
45 results on '"Lyon, Rebecca"'

3. Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial

Author

Paton, Nicholas, Hayden, Fred, Darbyshire, Janet, Lucas, Amy, Lorch, Ulrika, Freedman, Andrew, Knight, Richard, Julious, Stevan, Byrne, Rachel, Cubas Atienzar, Ana, Jones, Jayne, Williams, Chris, Song, Anna, Dixon, Jan, Alexandersson, Anja, Hatchard, Parys, Tilt, Emma, Titman, Andrew, Doce Carracedo, Ale, Chandran Gorner, Vatsi, Davies, Andrea, Woodhouse, Louis, Carlucci, Nicola, Okenyi, Emmanuel, Bula, Marcin, Dodd, Kate, Gibney, Jennifer, Dry, Lesley, Rashid Gardner, Zalina, Sammour, Amin, Cole, Christine, Rowland, Tim, Tsakiroglu, Maria, Yip, Vincent, Osanlou, Rostam, Stewart, Anna, Parker, Ben, Turgut, Tolga, Ahmed, Afshan, Starkey, Kay, Subin, Sujamole, Stockdale, Jennifer, Herring, Lisa, Baker, Jonathon, Oliver, Abigail, Pacurar, Mihaela, Owens, Dan, Munro, Alistair, Babbage, Gavin, Faust, Saul, Harvey, Matthew, Pratt, Danny, Nagra, Deepak, Vyas, Aashish, Khoo, Saye H, FitzGerald, Richard, Saunders, Geoffrey, Middleton, Calley, Ahmad, Shazaad, Edwards, Christopher J, Hadjiyiannakis, Dennis, Walker, Lauren, Lyon, Rebecca, Shaw, Victoria, Mozgunov, Pavel, Periselneris, Jimstan, Woods, Christie, Bullock, Katie, Hale, Colin, Reynolds, Helen, Downs, Nichola, Ewings, Sean, Buadi, Amanda, Cameron, David, Edwards, Thomas, Knox, Emma, Donovan-Banfield, I'ah, Greenhalf, William, Chiong, Justin, Lavelle-Langham, Lara, Jacobs, Michael, Northey, Josh, Painter, Wendy, Holman, Wayne, Lalloo, David G, Tetlow, Michelle, Hiscox, Julian A, Jaki, Thomas, Fletcher, Thomas, and Griffiths, Gareth

Published
2023
Full Text
View/download PDF

4. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial

Author

Munro, Alasdair P S, Feng, Shuo, Janani, Leila, Cornelius, Victoria, Aley, Parvinder K, Babbage, Gavin, Baxter, David, Bula, Marcin, Cathie, Katrina, Chatterjee, Krishna, Dodd, Kate, Enever, Yvanne, Qureshi, Ehsaan, Goodman, Anna L, Green, Christopher A, Harndahl, Linda, Haughney, John, Hicks, Alexander, van der Klaauw, Agatha A, Kanji, Nasir, Libri, Vincenzo, Llewelyn, Martin J, McGregor, Alastair C, Minassian, Angela M, Moore, Patrick, Mughal, Mehmood, Mujadidi, Yama F, Holliday, Kyra, Osanlou, Orod, Osanlou, Rostam, Owens, Daniel R, Pacurar, Mihaela, Palfreeman, Adrian, Pan, Daniel, Rampling, Tommy, Regan, Karen, Saich, Stephen, Bawa, Tanveer, Saralaya, Dinesh, Sharma, Sunil, Sheridan, Ray, Maallah, Mina, Thomson, Emma C, Todd, Shirley, Twelves, Chris, Read, Robert C, Charlton, Sue, Hallis, Bassam, Ramsay, Mary, Andrews, Nick, Lambe, Teresa, Nguyen-Van-Tam, Jonathan S, Snape, Matthew D, Liu, Xinxue, Faust, Saul N, Riordan, Andrew, Ustianowski, Andrew, Rogers, Chris, Katechia, Kashyap, Cooper, Alison, Freedman, Andrew, Hughes, Rachel, Grundy, Lynne, Tudor Jones, Lona, Harrison, Elizabeth, Snashall, Emma, Mallon, Lewis, Burton, Katharine, Storton, Kim, Munusamy, Malathi, Tandy, Bridget, Egbo, Akamino, Cox, Stephen, Ahmed, Nabeela Nazir, Shenoy, Anil, Bousfield, Rachel, Wixted, Donna, Gutteridge, Helen, Mansfield, Becky, Herbert, Christopher, Murira, Jennifer, Calderwood, James, Barker, Dominique, Brandon, Jacqueline, Tulloch, Hayley, Colquhoun, Suzie, Thorp, Helen, Radford, Helen, Evans, Julie, Baker, Helena, Thorpe, Jeanette, Batham, Sally, Hailstone, Jessica, Phillips, Rachael, Kumar, Dileep, Westwell, Fran, Sturdy, Ann, Barcella, Lara, Soussi, Najwa, Mpelembue, Mushiya, Raj, Sreena, Sharma, Rajni, Corrah, Tumena, John, Laurence, Whittington, Ashley, Roche, Siobhan, Wagstaff, Lynda, Farrier, Adam, Bisnauthsing, Karen, Abeywickrama, Movin, Spence, Niamh, Packham, Alice, Serafimova, Teona, Aslam, Suahil, McGreevy, Caitlin, Borca, Alessandro, DeLosSantosDominguez, Pamela, Palmer, Emily, Broadhead, Samantha, Farooqi, Sadaf, Piper, Jo, Weighell, Rowena, Pickup, Lorinda, Shamtally, Djamila, Domingo, Jason, Kourampa, Evgenia, Hale, Colin, Gibney, Jennifer, Stackpoole, Michael, Rashid-Gardner, Zalina, Lyon, Rebecca, McDonnell, Chloe, Cole, Christine, Stewart, Anna, McMillan, Gillian, Savage, Mary, Beckett, Helen, Moorbey, Chantelle, Desai, Amisha, Brown, Claire, Naker, Kush, Gokani, Karishma, Trinham, Charlotte, Sabine, Charlette, Moore, Sophie, Hurdover, Steve, Justice, Edwin, Stone, Megan, Plested, Emma, Ferreira Da Silva, Carla, White, Rachel, Robinson, Hannah, Turnbull, Iain, Morshead, Gertraud, Drake-Brockman, Rachael, Smith, Catherine, Li, Grace, Kasanyinga, Mwila, Clutterbuck, Elizabeth A, Bibi, Sagida, Singh, Michael, Champaneri, Trishna, Irwin, Margaret, Khan, Mohammed, Kownacka, Alicia, Nabunjo, Martha, Osuji, Carol, Hladkiwskyj, John, Galvin, Dominic, Patel, Gita, Grierson, Jacques, Males, Samantha, Askoolam, Krishna, Barry, Joshua, Mouland, Johanna, Longhurst, Beverley, Moon, Maria, Giddins, Beth, Pereira Dias Alves, Carlota, Richmond, Leah, Minnis, Christine, Baryschpolec, Sonia, Elliott, Scott, Fox, Lauren, Graham, Victoria, Baker, Natalie, Godwin, Kerry, Buttigieg, Karen, Knight, Chanice, Brown, Phillip, Lall, Paminder, Shaik, Imam, Chiplin, Emily, Brunt, Emily, Leung, Stephanie, Allen, Lauren, Thomas, Steve, Fraser, Sara, Choi, Bea, Gouriet, Jade, Perkins, Jonathan, Gowland, Andrew, Macdonald, Jonathan, Seenan, John Paul, Starinskij, Igor, Seaton, Andrew, Peters, Erica, Singh, Stephen, Gardside, Ben, Bonnaud, Avril, Davies, Ceri, Gordon, Elizabeth, Keenan, Samantha, Hall, Jane, Wilkins, Suzanne, Tasker, Suzanne, James, Rob, Seath, Ingrid, Littlewood, Kelly, Newman, Joseph, Boubriak, Iryna, Suggitt, Debbie, Haydock, Helen, Bennett, Sara, Woodyatt, Wiesia, Hughes, Kerry, Bell, Judith, Coughlan, Tricia, van Welsenes, Donald, Kamal, Mohammed, Cooper, Chris, Tunstall, Simon, Ronan, Nicholas, Cutts, Rebecca, Dare, Tracey, Yim, Yee Ting Nicole, Whittley, Sarah, Hamal, Shama, Ricamara, Marivic, Adams, Kirsty, Baker, Holly, Driver, Kimberley, Turner, Nicola, Rawlins, Todd, Roy, Subarna, Merida-Morillas, Marta, Sakagami, Yukari, Andrews, Antonette, Goncalvescordeiro, Lillian, Stokes, Matthew, Ambihapathy, Wythehi, Spencer, Joanne, Parungao, Nina, Berry, Lisa, Cullinane, James, Presland, Laura, Ross Russell, Amy, Warren, Sarah, Baker, Jonathan, Oliver, Abigail, Buadi, Amanda, Lee, Kim, Haskell, Louise, Romani, Rossana, Bentley, Ian, Whitbred, Tim, Fowler, Simon, Gavin, John, Magee, Alan, Watson, Tara, Nightingale, Kari, Marius, Phedra, Summerton, Eloise, Locke, Emily, Honey, Thomas, Lingwood, Aidan, de la Haye, Anastasia, Elliott, Ryan Stephen, Underwood, Karen, King, Mikayala, Davies-Dear, Sharon, Horsfall, Emily, Chalwin, Olivia, Burton, Holly, Edwards, Christopher J, Welham, Benjamin, Appleby, Kim, Dineen, Emily, Garrahy, Sarah, Hall, Fran, Ladikou, Eleni, Mullan, Dee, Hansen, Daniel, Campbell, Marion, Dos Santos, Filipa, Lakeman, Nicki, Branney, Debbie, Vamplew, Luke, Hogan, Alison, Frankham, Jorden, Wiselka, Martin, Vail, Denny, Wenn, Victoria, Renals, Valerie, Ellis, Kate, Lewis-Taylor, Jessica, Habash-Bailey, Haniah, Magan, Javier, and Hardy, Anna

Published
2022
Full Text
View/download PDF

5. Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial

Author

Donovan-Banfield, I’ah, Penrice-Randal, Rebekah, Goldswain, Hannah, Rzeszutek, Aleksandra M., Pilgrim, Jack, Bullock, Katie, Saunders, Geoffrey, Northey, Josh, Dong, Xiaofeng, Ryan, Yan, Reynolds, Helen, Tetlow, Michelle, Walker, Lauren E., FitzGerald, Richard, Hale, Colin, Lyon, Rebecca, Woods, Christie, Ahmad, Shazaad, Hadjiyiannakis, Dennis, Periselneris, Jimstan, Knox, Emma, Middleton, Calley, Lavelle-Langham, Lara, Shaw, Victoria, Greenhalf, William, Edwards, Thomas, Lalloo, David G., Edwards, Christopher J., Darby, Alistair C., Carroll, Miles W., Griffiths, Gareth, Khoo, Saye H., Hiscox, Julian A., and Fletcher, Thomas

Published
2022
Full Text
View/download PDF

6. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

Author

Riordan, Andrew, Ustianowski, Andrew, Rogers, Chris A, Hughes, Stephen, Longshaw, Laura, Stockport, Jane, Hughes, Rachel, Grundy, Lynne, Tudor Jones, Lona, Guha, Arpan, Snashall, Emma, Eadsforth, Tom, Reeder, Sally, Storton, Kim, Munusamy, Malathi, Tandy, Bridget, Egbo, Akamino, Cox, Stephen, Ahmed, Nabeela Nazir, Shenoy, Anil, Bousfield, Rachel, Wixted, Donna, Gutteridge, Helen, Mansfield, Becky, Herbert, Christopher, Holliday, Kyra, Calderwood, James, Barker, Dominique, Brandon, Jacqueline, Tulloch, Hayley, Colquhoun, Suzie, Thorp, Helen, Radford, Helen, Evans, Julie, Baker, Helena, Thorpe, Jeanette, Batham, Sally, Hailstone, Jessica, Phillips, Rachael, Kumar, Dileep, Westwell, Fran, Makia, Fiona, Hopkins, NinaSimone, Barcella, Lara, Mpelembue, Mushiya, dabagh, Maja, lang, Matilda, khan, Farida, Adebambo, Olumide, Chita, Sunder, Corrah, Tumena, Whittington, Ashley, John, Laurence, Roche, Siobhan, Wagstaff, Lynda, Farrier, Adam, Bisnauthsing, Karen, Serafimova, Teona, Nanino, Elisa, Cooney, Enya, Wilson-Goldsmith, Jaimie, Nguyen, Hanna, Mazzella, Andrea, Jackson, Beth, Aslam, Suahil, Bawa, Tanveer, Broadhead, Samantha, Farooqi, Sadaf, Piper, Jo, Weighell, Rowena, Pickup, Lorinda, Shamtally, Djamila, Domingo, Jason, Kourampa, Evgenia, Hale, Colin, Gibney, Jennifer, Stackpoole, Michael, Rashid-Gardner, Zalina, Lyon, Rebecca, McDonnell, Chloe, Cole, Christine, Stewart, Anna, McMillan, Gillian, Savage, Mary, Beckett, Helen, Moorbey, Chantelle, Desai, Amisha, Brown, Claire, Naker, Kush, Qureshi, Ehsaan, Trinham, Charlotte, Sabine, Charlotte, Moore, Sophie, Hurdover, Steve, Justice, Edwin, Smith, David, Plested, Emma, Ferreira Da Silva, Carla, White, Rachel, Robinson, Hannah, Cifuentes, Liliana, Morshead, Gertraud, Drake-Brockman, Rachael, Kinch, Patrick, Kasanyinga, Mwila, Clutterbuck, Elizabeth A., Bibi, Sagida, Stuart, Arabella SV, Shaw, Robert H, Singh, Michael, Champaneri, Trishna, Irwin, Margaret, Khan, Mohammed, Kownacka, Alicja, Nabunjo, Martha, Osuji, Carool, Hladkiwskyj, John, Galvin, Dominic, Patel, Gita, Mouland, Johanna, Longhurst, Beverley, Moon, Maria, Giddins, Beth, Pereira Dias Alves, Carlota, Richmond, Leah, Minnis, Christine, Baryschpolec, Sonia, Elliott, Scott, Fox, Lauren, Graham, Victoria, Baker, Natalie, Godwin, Kerry, Buttigieg, Karren, Knight, Chanice, Brown, Phillip, Lall, Paminder, Shaik, Imam, Chiplin, Emily, Brunt, Emily, Leung, Stephanie, Allen, Lauren, Thomas, Steve, Fraser, Sara, Choi, Bea, Gouriet, Jade, Freedman, Andrew, Perkins, Jonathan, Gowland, Andrew, Macdonald, Jonathan, Seenan, John Paul, Starinskij, Igor, Seaton, Andrew, Peters, Erica, Singh, Stephen, Gardside, Ben, Bonnaud, Avril, Davies, Ceri, Gordon, Elizabeth, Keenan, Samantha, Hall, Jane, Wilkins, Suzanne, Tasker, Suzanne, James, Rob, Seath, Ingrid, Littlewood, Kelly, Newman, Joseph, Boubriak, Iryna, Suggitt, Debbie, Haydock, Helen, Bennett, Sara, Woodyatt, Wiesia, Hughes, Kerry, Bell, Judith, Coughlan, Tricia, van Welsenes, Donald, Kamal, Mohammed, Cooper, Chris, Tunstall, Simon, Ronan, Nicholas, Cutts, Rebecca, Dare, Tracey, Yim, Yee Ting Nicole, Whittley, Sarah, Ricamara, Marivic, Hamal, Shama, Adams, Kirsty, Baker, Holly, Driver, Kimberley, Turner, Nicola, Rawlins, Todd, Roy, Subarna, Merida-Morillas, Marta, Sakagami, Yukari, Andrews, Antonette, Goncalves cordeiro, Lillian, Stokes, Matthew, Ambihapathy, Wythehi, Spencer, Joanne, Parungao, Nina, Berry, Lisa, Cullinane, James, Presland, Laura, Ross-Russell, Amy, Warren, Sarah, Baker, Jonathan, Oliver, Abigail, Buadi, Amanda, Lee, Kim, Haskell, Louise, Romani, Rossana, Bentley, Ian, Whitbred, Tim, Fowler, Simon, Gavin, John, Magee, Alan, Watson, Tara, Nightingale, Kari, Marius, Phedra, Summerton, Eloise, Locke, Emily, Honey, Thomas, Lingwood, Aidan, de la Haye, Anastasia, Elliott, Ryan Stephen, Underwood, Karen, King, Mikayala, Davies-Dear, Sharon, Horsfall, Emily, Chalwin, Olivia, Burton, Holly, Edwards, Christopher J, Welham, Benjamin, Garrahy, Sarah, Hall, Fran, Ladikou, Eleni, Mullan, Dee, Hansen, Daniel, Campbell, Marion, Dos Santos, Filipa, Habash-Bailey, Haniah, Lakeman, Nicki, Branney, Debbie, Vamplew, Luke, Hogan, Alison, Frankham, Jorden, Wiselka, Martin, Vail, Dennyl, Wenn, Victoria, Renals, Valerie, Ellis, Kate, Lewis-Taylor, Jessica, Magan, Javier, Hardy, Anna, Appleby, Kim, Munro, Alasdair P S, Janani, Leila, Cornelius, Victoria, Aley, Parvinder K, Babbage, Gavin, Baxter, David, Bula, Marcin, Cathie, Katrina, Chatterjee, Krishna, Dodd, Kate, Enever, Yvanne, Gokani, Karishma, Goodman, Anna L, Green, Christopher A, Harndahl, Linda, Haughney, John, Hicks, Alexander, van der Klaauw, Agatha A, Kwok, Jonathan, Lambe, Teresa, Libri, Vincenzo, Llewelyn, Martin J, McGregor, Alastair C, Minassian, Angela M, Moore, Patrick, Mughal, Mehmood, Mujadidi, Yama F, Murira, Jennifer, Osanlou, Orod, Osanlou, Rostam, Owens, Daniel R, Pacurar, Mihaela, Palfreeman, Adrian, Pan, Daniel, Rampling, Tommy, Regan, Karen, Saich, Stephen, Salkeld, Jo, Saralaya, Dinesh, Sharma, Sunil, Sheridan, Ray, Sturdy, Ann, Thomson, Emma C, Todd, Shirley, Twelves, Chris, Read, Robert C, Charlton, Sue, Hallis, Bassam, Ramsay, Mary, Andrews, Nick, Nguyen-Van-Tam, Jonathan S, Snape, Matthew D, Liu, Xinxue, and Faust, Saul N

Published
2021
Full Text
View/download PDF

10. Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial

Author

Khoo, Saye H, primary, FitzGerald, Richard, additional, Saunders, Geoffrey, additional, Middleton, Calley, additional, Ahmad, Shazaad, additional, Edwards, Christopher J, additional, Hadjiyiannakis, Dennis, additional, Walker, Lauren, additional, Lyon, Rebecca, additional, Shaw, Victoria, additional, Mozgunov, Pavel, additional, Periselneris, Jimstan, additional, Woods, Christie, additional, Bullock, Katie, additional, Hale, Colin, additional, Reynolds, Helen, additional, Downs, Nichola, additional, Ewings, Sean, additional, Buadi, Amanda, additional, Cameron, David, additional, Edwards, Thomas, additional, Knox, Emma, additional, Donovan-Banfield, I'ah, additional, Greenhalf, William, additional, Chiong, Justin, additional, Lavelle-Langham, Lara, additional, Jacobs, Michael, additional, Northey, Josh, additional, Painter, Wendy, additional, Holman, Wayne, additional, Lalloo, David G, additional, Tetlow, Michelle, additional, Hiscox, Julian A, additional, Jaki, Thomas, additional, Fletcher, Thomas, additional, Griffiths, Gareth, additional, Paton, Nicholas, additional, Hayden, Fred, additional, Darbyshire, Janet, additional, Lucas, Amy, additional, Lorch, Ulrika, additional, Freedman, Andrew, additional, Knight, Richard, additional, Julious, Stevan, additional, Byrne, Rachel, additional, Cubas Atienzar, Ana, additional, Jones, Jayne, additional, Williams, Chris, additional, Song, Anna, additional, Dixon, Jan, additional, Alexandersson, Anja, additional, Hatchard, Parys, additional, Tilt, Emma, additional, Titman, Andrew, additional, Doce Carracedo, Ale, additional, Chandran Gorner, Vatsi, additional, Davies, Andrea, additional, Woodhouse, Louis, additional, Carlucci, Nicola, additional, Okenyi, Emmanuel, additional, Bula, Marcin, additional, Dodd, Kate, additional, Gibney, Jennifer, additional, Dry, Lesley, additional, Rashid Gardner, Zalina, additional, Sammour, Amin, additional, Cole, Christine, additional, Rowland, Tim, additional, Tsakiroglu, Maria, additional, Yip, Vincent, additional, Osanlou, Rostam, additional, Stewart, Anna, additional, Parker, Ben, additional, Turgut, Tolga, additional, Ahmed, Afshan, additional, Starkey, Kay, additional, Subin, Sujamole, additional, Stockdale, Jennifer, additional, Herring, Lisa, additional, Baker, Jonathon, additional, Oliver, Abigail, additional, Pacurar, Mihaela, additional, Owens, Dan, additional, Munro, Alistair, additional, Babbage, Gavin, additional, Faust, Saul, additional, Harvey, Matthew, additional, Pratt, Danny, additional, Nagra, Deepak, additional, and Vyas, Aashish, additional

Published
2023
Full Text
View/download PDF

12. A Randomised -Controlled Phase 2 trial of Molnupiravir in Unvaccinated and Vaccinated Individuals with Early SARS-CoV-2

Author

Khoo, Saye H, primary, FitzGerald, Richard, additional, Saunders, Geoffrey, additional, Middleton, Calley, additional, Ahmad, Shazaad, additional, Edwards, Christopher J, additional, Hadjiyiannakis, Dennis, additional, Walker, Lauren, additional, Lyon, Rebecca, additional, Shaw, Victoria, additional, Mozgunov, Pavel, additional, Periselneris, Jimstan, additional, Woods, Christie, additional, Bullock, Katie, additional, Hale, Colin, additional, Reynolds, Helen, additional, Downs, Nichola, additional, Ewings, Sean, additional, Buadi, Amanda, additional, Cameron, David, additional, Edwards, Thomas, additional, Knox, Emma, additional, Donovan-Banfield, I’ah, additional, Greenhalf, William, additional, Chiong, Justin, additional, Lavelle-Langham, Lara, additional, Jacobs, Michael, additional, Painter, Wendy, additional, Holman, Wayne, additional, Lalloo, David G, additional, Tetlow, Michelle, additional, Hiscox, Julian A, additional, Jaki, Thomas, additional, Fletcher, Thomas, additional, and Griffiths, Gareth, additional

Published
2022
Full Text
View/download PDF

13. Characterisation of SARS-CoV-2 genomic variations in response to molnupiravir treatment in the AGILE Phase IIa clinical trial.

Author

Fletcher, Thomas, primary, Donovan-Banfield, I'ah, additional, Penrice-Randal, Rebekah, additional, Goldswain, Hannah, additional, Rzeszutek, Aleksandra, additional, Pilgrim, Jack, additional, Bullock, Katie, additional, Saunders, Geoffrey, additional, Northey, Josh, additional, Dong, Xiaofeng, additional, Ryan, Yan, additional, Reynolds, Helen, additional, Tetlow, Michelle, additional, Walker, Lauren, additional, FitzGerald, Richard, additional, Hale, Colin, additional, Lyon, Rebecca, additional, Woods, Christie, additional, Ahmad, Shazaad, additional, Hadjiyiannakis, Dennis, additional, Periselneris, Jimstan, additional, Knox, Emma, additional, Middleton, Calley, additional, Lavelle-Langham, Lara, additional, Shaw, Victoria, additional, Greenhalf, William, additional, Edwards, Thomas, additional, Lalloo, David, additional, Edwards, Christopher, additional, Darby, Alistair, additional, Carroll, Miles, additional, Griffiths, Gareth, additional, Khoo, Saye, additional, and Hiscox, Julian, additional

Published
2022
Full Text
View/download PDF

14. Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Author

FitzGerald, Richard, primary, Dickinson, Laura, additional, Else, Laura, additional, Fletcher, Thomas, additional, Hale, Colin, additional, Amara, Alieu, additional, Walker, Lauren, additional, Penchala, Sujan Dilly, additional, Lyon, Rebecca, additional, Shaw, Victoria, additional, Greenhalf, William, additional, Bullock, Katie, additional, Lavelle-Langham, Lara, additional, Reynolds, Helen, additional, Painter, Wendy, additional, Holman, Wayne, additional, Ewings, Sean, additional, Griffiths, Gareth, additional, and Khoo, Saye, additional

Published
2022
Full Text
View/download PDF

15. Pharmacokinetics of β-d-N4-hydroxycytidine, the active metabolite of prodrug molnupiravir, in non-plasma compartments of patients with SARS-CoV-2 infection

Author

FitzGerald, Richard, primary, Dickinson, Laura, additional, Else, Laura, additional, Fletcher, Thomas, additional, Hale, Colin, additional, Amara, Alieu, additional, Walker, Lauren, additional, Dilly Penchala, Sujan, additional, Lyon, Rebecca, additional, Shaw, Victoria, additional, Greenhalf, William, additional, Lavelle-Langham, Lara, additional, Reynolds, Helen, additional, Painter, Wendy, additional, Holman, Wayne, additional, Ewings, Sean, additional, Griffiths, Gareth, additional, and Khoo, Saye, additional

Published
2021
Full Text
View/download PDF

16. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

Author

Munro, Alasdair P S, primary, Janani, Leila, additional, Cornelius, Victoria, additional, Aley, Parvinder K, additional, Babbage, Gavin, additional, Baxter, David, additional, Bula, Marcin, additional, Cathie, Katrina, additional, Chatterjee, Krishna, additional, Dodd, Kate, additional, Enever, Yvanne, additional, Gokani, Karishma, additional, Goodman, Anna L, additional, Green, Christopher A, additional, Harndahl, Linda, additional, Haughney, John, additional, Hicks, Alexander, additional, van der Klaauw, Agatha A, additional, Kwok, Jonathan, additional, Lambe, Teresa, additional, Libri, Vincenzo, additional, Llewelyn, Martin J, additional, McGregor, Alastair C, additional, Minassian, Angela M, additional, Moore, Patrick, additional, Mughal, Mehmood, additional, Mujadidi, Yama F, additional, Murira, Jennifer, additional, Osanlou, Orod, additional, Osanlou, Rostam, additional, Owens, Daniel R, additional, Pacurar, Mihaela, additional, Palfreeman, Adrian, additional, Pan, Daniel, additional, Rampling, Tommy, additional, Regan, Karen, additional, Saich, Stephen, additional, Salkeld, Jo, additional, Saralaya, Dinesh, additional, Sharma, Sunil, additional, Sheridan, Ray, additional, Sturdy, Ann, additional, Thomson, Emma C, additional, Todd, Shirley, additional, Twelves, Chris, additional, Read, Robert C, additional, Charlton, Sue, additional, Hallis, Bassam, additional, Ramsay, Mary, additional, Andrews, Nick, additional, Nguyen-Van-Tam, Jonathan S, additional, Snape, Matthew D, additional, Liu, Xinxue, additional, Faust, Saul N, additional, Riordan, Andrew, additional, Ustianowski, Andrew, additional, Rogers, Chris A, additional, Hughes, Stephen, additional, Longshaw, Laura, additional, Stockport, Jane, additional, Hughes, Rachel, additional, Grundy, Lynne, additional, Tudor Jones, Lona, additional, Guha, Arpan, additional, Snashall, Emma, additional, Eadsforth, Tom, additional, Reeder, Sally, additional, Storton, Kim, additional, Munusamy, Malathi, additional, Tandy, Bridget, additional, Egbo, Akamino, additional, Cox, Stephen, additional, Ahmed, Nabeela Nazir, additional, Shenoy, Anil, additional, Bousfield, Rachel, additional, Wixted, Donna, additional, Gutteridge, Helen, additional, Mansfield, Becky, additional, Herbert, Christopher, additional, Holliday, Kyra, additional, Calderwood, James, additional, Barker, Dominique, additional, Brandon, Jacqueline, additional, Tulloch, Hayley, additional, Colquhoun, Suzie, additional, Thorp, Helen, additional, Radford, Helen, additional, Evans, Julie, additional, Baker, Helena, additional, Thorpe, Jeanette, additional, Batham, Sally, additional, Hailstone, Jessica, additional, Phillips, Rachael, additional, Kumar, Dileep, additional, Westwell, Fran, additional, Makia, Fiona, additional, Hopkins, NinaSimone, additional, Barcella, Lara, additional, Mpelembue, Mushiya, additional, dabagh, Maja, additional, lang, Matilda, additional, khan, Farida, additional, Adebambo, Olumide, additional, Chita, Sunder, additional, Corrah, Tumena, additional, Whittington, Ashley, additional, John, Laurence, additional, Roche, Siobhan, additional, Wagstaff, Lynda, additional, Farrier, Adam, additional, Bisnauthsing, Karen, additional, Serafimova, Teona, additional, Nanino, Elisa, additional, Cooney, Enya, additional, Wilson-Goldsmith, Jaimie, additional, Nguyen, Hanna, additional, Mazzella, Andrea, additional, Jackson, Beth, additional, Aslam, Suahil, additional, Bawa, Tanveer, additional, Broadhead, Samantha, additional, Farooqi, Sadaf, additional, Piper, Jo, additional, Weighell, Rowena, additional, Pickup, Lorinda, additional, Shamtally, Djamila, additional, Domingo, Jason, additional, Kourampa, Evgenia, additional, Hale, Colin, additional, Gibney, Jennifer, additional, Stackpoole, Michael, additional, Rashid-Gardner, Zalina, additional, Lyon, Rebecca, additional, McDonnell, Chloe, additional, Cole, Christine, additional, Stewart, Anna, additional, McMillan, Gillian, additional, Savage, Mary, additional, Beckett, Helen, additional, Moorbey, Chantelle, additional, Desai, Amisha, additional, Brown, Claire, additional, Naker, Kush, additional, Qureshi, Ehsaan, additional, Trinham, Charlotte, additional, Sabine, Charlotte, additional, Moore, Sophie, additional, Hurdover, Steve, additional, Justice, Edwin, additional, Smith, David, additional, Plested, Emma, additional, Ferreira Da Silva, Carla, additional, White, Rachel, additional, Robinson, Hannah, additional, Cifuentes, Liliana, additional, Morshead, Gertraud, additional, Drake-Brockman, Rachael, additional, Kinch, Patrick, additional, Kasanyinga, Mwila, additional, Clutterbuck, Elizabeth A., additional, Bibi, Sagida, additional, Stuart, Arabella SV, additional, Shaw, Robert H, additional, Singh, Michael, additional, Champaneri, Trishna, additional, Irwin, Margaret, additional, Khan, Mohammed, additional, Kownacka, Alicja, additional, Nabunjo, Martha, additional, Osuji, Carool, additional, Hladkiwskyj, John, additional, Galvin, Dominic, additional, Patel, Gita, additional, Mouland, Johanna, additional, Longhurst, Beverley, additional, Moon, Maria, additional, Giddins, Beth, additional, Pereira Dias Alves, Carlota, additional, Richmond, Leah, additional, Minnis, Christine, additional, Baryschpolec, Sonia, additional, Elliott, Scott, additional, Fox, Lauren, additional, Graham, Victoria, additional, Baker, Natalie, additional, Godwin, Kerry, additional, Buttigieg, Karren, additional, Knight, Chanice, additional, Brown, Phillip, additional, Lall, Paminder, additional, Shaik, Imam, additional, Chiplin, Emily, additional, Brunt, Emily, additional, Leung, Stephanie, additional, Allen, Lauren, additional, Thomas, Steve, additional, Fraser, Sara, additional, Choi, Bea, additional, Gouriet, Jade, additional, Freedman, Andrew, additional, Perkins, Jonathan, additional, Gowland, Andrew, additional, Macdonald, Jonathan, additional, Seenan, John Paul, additional, Starinskij, Igor, additional, Seaton, Andrew, additional, Peters, Erica, additional, Singh, Stephen, additional, Gardside, Ben, additional, Bonnaud, Avril, additional, Davies, Ceri, additional, Gordon, Elizabeth, additional, Keenan, Samantha, additional, Hall, Jane, additional, Wilkins, Suzanne, additional, Tasker, Suzanne, additional, James, Rob, additional, Seath, Ingrid, additional, Littlewood, Kelly, additional, Newman, Joseph, additional, Boubriak, Iryna, additional, Suggitt, Debbie, additional, Haydock, Helen, additional, Bennett, Sara, additional, Woodyatt, Wiesia, additional, Hughes, Kerry, additional, Bell, Judith, additional, Coughlan, Tricia, additional, van Welsenes, Donald, additional, Kamal, Mohammed, additional, Cooper, Chris, additional, Tunstall, Simon, additional, Ronan, Nicholas, additional, Cutts, Rebecca, additional, Dare, Tracey, additional, Yim, Yee Ting Nicole, additional, Whittley, Sarah, additional, Ricamara, Marivic, additional, Hamal, Shama, additional, Adams, Kirsty, additional, Baker, Holly, additional, Driver, Kimberley, additional, Turner, Nicola, additional, Rawlins, Todd, additional, Roy, Subarna, additional, Merida-Morillas, Marta, additional, Sakagami, Yukari, additional, Andrews, Antonette, additional, Goncalves cordeiro, Lillian, additional, Stokes, Matthew, additional, Ambihapathy, Wythehi, additional, Spencer, Joanne, additional, Parungao, Nina, additional, Berry, Lisa, additional, Cullinane, James, additional, Presland, Laura, additional, Ross-Russell, Amy, additional, Warren, Sarah, additional, Baker, Jonathan, additional, Oliver, Abigail, additional, Buadi, Amanda, additional, Lee, Kim, additional, Haskell, Louise, additional, Romani, Rossana, additional, Bentley, Ian, additional, Whitbred, Tim, additional, Fowler, Simon, additional, Gavin, John, additional, Magee, Alan, additional, Watson, Tara, additional, Nightingale, Kari, additional, Marius, Phedra, additional, Summerton, Eloise, additional, Locke, Emily, additional, Honey, Thomas, additional, Lingwood, Aidan, additional, de la Haye, Anastasia, additional, Elliott, Ryan Stephen, additional, Underwood, Karen, additional, King, Mikayala, additional, Davies-Dear, Sharon, additional, Horsfall, Emily, additional, Chalwin, Olivia, additional, Burton, Holly, additional, Edwards, Christopher J, additional, Welham, Benjamin, additional, Garrahy, Sarah, additional, Hall, Fran, additional, Ladikou, Eleni, additional, Mullan, Dee, additional, Hansen, Daniel, additional, Campbell, Marion, additional, Dos Santos, Filipa, additional, Habash-Bailey, Haniah, additional, Lakeman, Nicki, additional, Branney, Debbie, additional, Vamplew, Luke, additional, Hogan, Alison, additional, Frankham, Jorden, additional, Wiselka, Martin, additional, Vail, Dennyl, additional, Wenn, Victoria, additional, Renals, Valerie, additional, Ellis, Kate, additional, Lewis-Taylor, Jessica, additional, Magan, Javier, additional, Hardy, Anna, additional, and Appleby, Kim, additional

Published
2021
Full Text
View/download PDF

17. AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter

Author

Griffiths, Gareth O, FitzGerald, Richard, Jaki, Thomas, Corkhill, Andrea, Reynolds, Helen, Ewings, Sean, Condie, Susannah, Tilt, Emma, Johnson, Lucy, Radford, Mike, Simpson, Catherine, Saunders, Geoffrey, Yeats, Sara, Mozgunov, Pavel, Tansley-Hancock, Olana, Martin, Karen, Downs, Nichola, Eberhart, Izabela, Martin, Jonathan WB, Goncalves, Cristiana, Song, Anna, Fletcher, Tom, Byrne, Kelly, Lalloo, David G, Owen, Andrew, Jacobs, Michael, Walker, Lauren, Lyon, Rebecca, Woods, Christie, Gibney, Jennifer, Chiong, Justin, Chandiwana, Nomathemba, Jacob, Shevin, Lamorde, Mohammed, Orrell, Catherine, Pirmohamed, Munir, Khoo, Saye, AGILE Investigators, Desmond Tutu HIV Centre, Faculty of Health Sciences, Jaki, Thomas [0000-0002-1096-188X], and Apollo - University of Cambridge Repository

Subjects
Medicine (General), medicine.medical_specialty, Population, Psychological intervention, Medicine (miscellaneous), 030204 cardiovascular system & hematology, wc_500, Update, law.invention, Cohort Studies, 03 medical and health sciences, R5-920, 0302 clinical medicine, Randomized controlled trial, law, wc_506, wc_505, medicine, Clinical endpoint, Master protocol, Humans, Pharmacology (medical), Medical physics, 030212 general & internal medicine, education, Pandemics, Protocol (science), Randomised controlled trial, education.field_of_study, business.industry, SARS-CoV-2, COVID-19, wb_102.5, Phase I/II, Bayesian, 3. Good health, Identification (information), Treatment Outcome, business, Platform study, Agile software development, Cohort study
Abstract

Funder: Unitaid, BACKGROUND: There is an urgent unmet clinical need for the identification of novel therapeutics for the treatment of COVID-19. A number of COVID-19 late phase trial platforms have been developed to investigate (often repurposed) drugs both in the UK and globally (e.g. RECOVERY led by the University of Oxford and SOLIDARITY led by WHO). There is a pressing need to investigate novel candidates within early phase trial platforms, from which promising candidates can feed into established later phase platforms. AGILE grew from a UK-wide collaboration to undertake early stage clinical evaluation of candidates for SARS-CoV-2 infection to accelerate national and global healthcare interventions. METHODS/DESIGN: AGILE is a seamless phase I/IIa platform study to establish the optimum dose, determine the activity and safety of each candidate and recommend whether it should be evaluated further. Each candidate is evaluated in its own trial, either as an open label single arm healthy volunteer study or in patients, randomising between candidate and control usually in a 2:1 allocation in favour of the candidate. Each dose is assessed sequentially for safety usually in cohorts of 6 patients. Once a phase II dose has been identified, efficacy is assessed by seamlessly expanding into a larger cohort. AGILE is completely flexible in that the core design in the master protocol can be adapted for each candidate based on prior knowledge of the candidate (i.e. population, primary endpoint and sample size can be amended). This information is detailed in each candidate specific trial protocol of the master protocol. DISCUSSION: Few approved treatments for COVID-19 are available such as dexamethasone, remdesivir and tocilizumab in hospitalised patients. The AGILE platform aims to rapidly identify new efficacious and safe treatments to help end the current global COVID-19 pandemic. We currently have three candidate specific trials within this platform study that are open to recruitment. TRIAL REGISTRATION: EudraCT Number: 2020-001860-27 14 March 2020 ClinicalTrials.gov Identifier: NCT04746183 19 February 2021 ISRCTN reference: 27106947.

Published
2021
Full Text
View/download PDF

18. An open label, adaptive, phase 1 trial of high-dose oral nitazoxanide in healthy volunteers: an antiviral candidate for SARS-CoV-2

Author

Walker, Lauren E, primary, FitzGerald, Richard, additional, Saunders, Geoffrey, additional, Lyon, Rebecca, additional, Fisher, Michael, additional, Martin, Karen, additional, Eberhart, Izabela, additional, Woods, Christie, additional, Ewings, Sean, additional, Hale, Colin, additional, Rajoli, Rajith KR, additional, Else, Laura, additional, Dilly-Penchala, Sujan, additional, Amara, Alieu, additional, Lalloo, David G, additional, Jacobs, Michael, additional, Pertinez, Henry, additional, Hatchard, Parys, additional, Waugh, Robert, additional, Lawrence, Megan, additional, Johnson, Lucy, additional, Fines, Keira, additional, Reynolds, Helen, additional, Rowland, Timothy, additional, Crook, Rebecca, additional, Byrne, Kelly, additional, Mozgunov, Pavel, additional, Jaki, Thomas, additional, Khoo, Saye, additional, Owen, Andrew, additional, Griffiths, Gareth, additional, and Fletcher, Thomas E, additional

Published
2021
Full Text
View/download PDF

19. Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study

Author

Khoo, Saye H, primary, Fitzgerald, Richard, additional, Fletcher, Thomas, additional, Ewings, Sean, additional, Jaki, Thomas, additional, Lyon, Rebecca, additional, Downs, Nichola, additional, Walker, Lauren, additional, Tansley-Hancock, Olana, additional, Greenhalf, William, additional, Woods, Christie, additional, Reynolds, Helen, additional, Marwood, Ellice, additional, Mozgunov, Pavel, additional, Adams, Emily, additional, Bullock, Katie, additional, Holman, Wayne, additional, Bula, Marcin D, additional, Gibney, Jennifer L, additional, Saunders, Geoffrey, additional, Corkhill, Andrea, additional, Hale, Colin, additional, Thorne, Kerensa, additional, Chiong, Justin, additional, Condie, Susannah, additional, Pertinez, Henry, additional, Painter, Wendy, additional, Wrixon, Emma, additional, Johnson, Lucy, additional, Yeats, Sara, additional, Mallard, Kim, additional, Radford, Mike, additional, Fines, Keira, additional, Shaw, Victoria, additional, Owen, Andrew, additional, Lalloo, David G, additional, Jacobs, Michael, additional, and Griffiths, Gareth, additional

Published
2021
Full Text
View/download PDF

20. Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase 1, dose-escalating, randomised controlled study

Author

Khoo, Saye H, primary, FitzGerald, Richard, additional, Fletcher, Thomas, additional, Ewings, Sean, additional, Jaki, Thomas, additional, Lyon, Rebecca, additional, Downs, Nichola, additional, Walker, Lauren, additional, Tansley-Hancock, Olana, additional, Greenhalf, William, additional, Woods, Christie, additional, Reynolds, Helen, additional, Marwood, Ellice, additional, Mozgunov, Pavel, additional, Adams, Emily, additional, Bullock, Katie, additional, Holman, Wayne, additional, Bula, Marcin D, additional, Gibney, Jennifer L, additional, Saunders, Geoffrey, additional, Corkhill, Andrea, additional, Hale, Colin, additional, Thorne, Kerensa, additional, Chiong, Justin, additional, Condie, Susannah, additional, Pertinez, Henry, additional, Painter, Wendy, additional, Wrixon, Emma, additional, Johnson, Lucy, additional, Yeats, Sara, additional, Mallard, Kim, additional, Radford, Mike, additional, Fines, Keira, additional, Shaw, Victoria, additional, Owen, Andrew, additional, Lalloo, David G, additional, Jacobs, Michael, additional, and Griffiths, Gareth, additional

Published
2021
Full Text
View/download PDF

21. Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2:a Phase I, open-label, dose-escalating, randomized controlled study

Author

Khoo, Saye H, Fitzgerald, Richard, Fletcher, Thomas, Ewings, Sean, Jaki, Thomas, Lyon, Rebecca, Downs, Nichola, Walker, Lauren, Tansley-Hancock, Olana, Greenhalf, William, Woods, Christie, Reynolds, Helen, Marwood, Ellice, Mozgunov, Pavel, Adams, Emily, Bullock, Katie, Holman, Wayne, Bula, Marcin D, Gibney, Jennifer L, Saunders, Geoffrey, Corkhill, Andrea, Hale, Colin, Thorne, Kerensa, Chiong, Justin, Condie, Susannah, Pertinez, Henry, Painter, Wendy, Wrixon, Emma, Johnson, Lucy, Yeats, Sara, Mallard, Kim, Radford, Mike, Fines, Keira, Shaw, Victoria, Owen, Andrew, Lalloo, David G, Jacobs, Michael, Griffiths, Gareth, Khoo, Saye H, Fitzgerald, Richard, Fletcher, Thomas, Ewings, Sean, Jaki, Thomas, Lyon, Rebecca, Downs, Nichola, Walker, Lauren, Tansley-Hancock, Olana, Greenhalf, William, Woods, Christie, Reynolds, Helen, Marwood, Ellice, Mozgunov, Pavel, Adams, Emily, Bullock, Katie, Holman, Wayne, Bula, Marcin D, Gibney, Jennifer L, Saunders, Geoffrey, Corkhill, Andrea, Hale, Colin, Thorne, Kerensa, Chiong, Justin, Condie, Susannah, Pertinez, Henry, Painter, Wendy, Wrixon, Emma, Johnson, Lucy, Yeats, Sara, Mallard, Kim, Radford, Mike, Fines, Keira, Shaw, Victoria, Owen, Andrew, Lalloo, David G, Jacobs, Michael, and Griffiths, Gareth

Abstract

Objectives AGILE is a Phase Ib/IIa platform for rapidly evaluating COVID-19 treatments. In this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in participants with early symptomatic infection. Methods We undertook a dose-escalating, open-label, randomized-controlled (standard-of-care) Bayesian adaptive Phase I trial at the Royal Liverpool and Broadgreen Clinical Research Facility. Participants (adult outpatients with PCR-confirmed SARS-CoV-2 infection within 5 days of symptom onset) were randomized 2:1 in groups of 6 participants to 300, 600 and 800 mg doses of molnupiravir orally, twice daily for 5 days or control. A dose was judged unsafe if the probability of 30% or greater dose-limiting toxicity (the primary outcome) over controls was 25% or greater. Secondary outcomes included safety, clinical progression, pharmacokinetics and virological responses. Results Of 103 participants screened, 18 participants were enrolled between 17 July and 30 October 2020. Molnupiravir was well tolerated at 300, 600 and 800 mg doses with no serious or severe adverse events. Overall, 4 of 4 (100%), 4 of 4 (100%) and 1 of 4 (25%) of the participants receiving 300, 600 and 800 mg molnupiravir, respectively, and 5 of 6 (83%) controls, had at least one adverse event, all of which were mild (≤grade 2). The probability of ≥30% excess toxicity over controls at 800 mg was estimated at 0.9%. Conclusions Molnupiravir was safe and well tolerated; a dose of 800 mg twice daily for 5 days was recommended for Phase II evaluation.

Published
2021

22. AGILE: A Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment: An update to the structured summary of a study protocol for a randomised platform trial letter

Author

Griffiths, Gareth Owen, primary, FitzGerald, Richard, additional, Jaki, Thomas, additional, Corkhill, Andrea, additional, Reynolds, Helen, additional, Ewings, Sean, additional, Condie, Susannah, additional, Tilt, Emma, additional, Johnson, Lucy, additional, Radford, Mike, additional, Simpson, Catherine, additional, Saunders, Geoffrey, additional, Yeats, Sara, additional, Mozgunov, Pavel, additional, Tansley-Hancock, Olana, additional, Martin, Karen, additional, Downs, Nichola, additional, Eberhart, Izabela, additional, Martin, Jonathan William Brian, additional, Goncalves, Cristiana, additional, Song, Anna, additional, Fletcher, Tom, additional, Byrne, Kelly, additional, Lalloo, David Griffith, additional, Owen, Andrew, additional, Jacobs, Michael, additional, Walker, Lauren, additional, Lyon, Rebecca, additional, Woods, Christie, additional, Gibney, Jennifer, additional, Chiong, Justin, additional, Chandiwana, Nomathemba, additional, Jacob, Shevin, additional, Lamorde, Mohammed, additional, Orrell, Catherine, additional, Pirmohamed, Munir, additional, and Khoo, Saye, additional

Published
2021
Full Text
View/download PDF

23. An Open Label, Adaptive, Phase 1 Trial of High‐Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS‐CoV‐2.

Author

Walker, Lauren E., FitzGerald, Richard, Saunders, Geoffrey, Lyon, Rebecca, Fisher, Michael, Martin, Karen, Eberhart, Izabela, Woods, Christie, Ewings, Sean, Hale, Colin, Rajoli, Rajith K. R., Else, Laura, Dilly‐Penchala, Sujan, Amara, Alieu, Lalloo, David G., Jacobs, Michael, Pertinez, Henry, Hatchard, Parys, Waugh, Robert, and Lawrence, Megan

Subjects
CORONAVIRUS disease treatment, COVID-19, SARS-CoV-2, VOLUNTEERS, VOLUNTEER service, ANTIPARASITIC agents
Abstract

Repurposing approved drugs may rapidly establish effective interventions during a public health crisis. This has yielded immunomodulatory treatments for severe coronavirus disease 2019 (COVID‐19), but repurposed antivirals have not been successful to date because of redundancy of the target in vivo or suboptimal exposures at studied doses. Nitazoxanide is a US Food and Drug Administration (FDA) approved antiparasitic medicine, that physiologically‐based pharmacokinetic (PBPK) modeling has indicated may provide antiviral concentrations across the dosing interval, when repurposed at higher than approved doses. Within the AGILE trial platform (NCT04746183) an open label, adaptive, phase I trial in healthy adult participants was undertaken with high‐dose nitazoxanide. Participants received 1,500 mg nitazoxanide orally twice‐daily with food for 7 days. Primary outcomes were safety, tolerability, optimum dose, and schedule. Intensive pharmacokinetic (PK) sampling was undertaken day 1 and 5 with minimum concentration (Cmin) sampling on days 3 and 7. Fourteen healthy participants were enrolled between February 18 and May 11, 2021. All 14 doses were completed by 10 of 14 participants. Nitazoxanide was safe and with no significant adverse events. Moderate gastrointestinal disturbance (loose stools or diarrhea) occurred in 8 participants (57.1%), with urine and sclera discoloration in 12 (85.7%) and 9 (64.3%) participants, respectively, without clinically significant bilirubin elevation. This was self‐limiting and resolved upon drug discontinuation. PBPK predictions were confirmed on day 1 but with underprediction at day 5. Median Cmin was above the in vitro target concentration on the first dose and maintained throughout. Nitazoxanide administered at 1,500 mg b.i.d. with food was safe with acceptable tolerability a phase Ib/IIa study is now being initiated in patients with COVID‐19. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

25. Research Design in Marital Adjustment Studies.

Author

Croake, James W. and Lyon, Rebecca S.

Abstract

The numerous marital adjustment studies which exist in the literature are confounded by basic design problems. Marital stability should be the baseline for data. It is then possible to discuss "happiness,""success,""adjustment," and "satisfaction." (Author)

Published
1978

29. Blueberry sauce

Author

Lyon, Rebecca

Abstract

Heat applesauce to bubbling, stir in lots of blueberries (or other fruit, can be frozen), and serve warm over pancakes or waffles.--Rebecca Lyon, PO Box 34, Wetmore, MI […]

Published
2000

30. HIDDEN HOME VIDEOS: SURREPTITIOUS VIDEO SURVEILLANCE IN DIVORCE.

Author

LYON, REBECCA V.

Subjects
VIDEO surveillance laws, VIDEO recording, DIVORCE lawsuits, WIRETAPPING laws, ELECTRONIC article surveillance systems
Abstract

The article focuses on the laws regarding the video surveillance and the role of surreptitious video surveillance in misleading the divorce proceeding. Topics discussed include role of judicial action in preventing spouses from video recording for using them in divorce proceedings, analysis of the Federal Wiretapping Statute and analysis of lack of protection in video surveillance law. It further discusses different laws made for video surveillance in different states.

Published
2014

33. He cheated Now what?

Author

Lyon, Rebecca

Subjects
MAN-woman relationships, INTERPERSONAL relations, MARRIED people, MARRIAGE, HONESTY
Abstract

Shares the author's experience with her husband's womanizing. Initial reaction when her husband admitted that he was having an affair; Background on their relationship; Coping with anger and pain.

Published
2005

34. PCR amplification of SNP loci from crude DNA for large-scale genotyping of oomycetes.

Author

Jian Hu, Lyon, Rebecca, Yuxin Zhou, and Lamour, Kurt

Subjects
*OOMYCETES, *EUKARYOTE phylogeny, *SINGLE nucleotide polymorphisms, *PHYTOPHTHORA, *NUCLEIC acid isolation methods
Abstract

Similar to other eukaryotes, single nucleotide polymorphism (SNP) markers are abundant in many oomycete plant pathogen genomes. High resolution DNA melting analysis (HR-DMA) is a cost-effective method for SNP genotyping, but like many SNP marker technologies, is limited by the amount and quality of template DNA. We describe PCR preamplification of Phytophthora and Peronospora SNP loci from crude DNA extracted from a small amount of mycelium and/or infected plant tissue to produce sufficient template to genotype at least 10 000 SNPs. The approach is fast, inexpensive, requires minimal biological material and should be useful for many organisms in a variety of contexts. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

35. Research design in marital adjustment studies

Author

Croake, James W. and Lyon, Rebecca S.

Abstract

Despite the proliferation of marital adjustment studies, basic methodological problems remain unresolved. Not the least of these is the lack of a clearly defined and uniformly understood concept of what is being studied. The purpose of the present paper is to illuminate methodological problems which are specific to research in marital adjustment. Therefore, problems which would be true for all research in the behavioral studies and are not specific to marital adjustment are either not included or are discussed minimally. More detailed research is available elsewhere that relates to but is not the same as marital adjustment. Research in marital therapy would be an example of related data (Gurman, 1975).

Published
1978
Full Text
View/download PDF

37. Chat to us!

Author

Bevis, Brita, Dunn, Lesley, Workman, Shannon, Giblin, S., Hutchins, Stacey, Lord-Lyon, Rebecca, Wood, Dawn, Emerson, Irene, Walters, Clare, and Marsden, Caroline

Published
2017

41. Chat to us!

Author

Lord-Lyon, Rebecca, Perry, Irene, Myers, Sarah, Farrell, Shannon O, Johnson, Ann, Lock, Sarah, Jackson, Amanda, Williams, Tina, Pascoe, Tracey, and Thomas, Stephanie

Published
2016

42. Population Structure of Late Blight (Phytophthora infestans) in Colombia and Ecuador and Downy Mildew (Peronospora farinosa f. sp. spinaciae) on Spinach in Arizona and California

Author

Lyon, Rebecca Marie

Subjects
Agriculture, Genetics, Plant Pathology
Abstract

In this study, Phytophthora infestans and Peronospora farinosa f. sp. spinaciae populations were analyzed using single nucleotide polymorphisms (SNPs). In Ecuador and Colombia, Phytophthora infestans causes significant damage to potato and tomato and the epidemiology is known to be highly clonal. Our objective was to measure population structure within the context of this clonal epidemiology using both synonymous and nonsynonymous markers. Candidate SNP sites were selected by comparing the draft genomes of the Ecuadorian isolates EC1-3527 and EC1-3626. Genotypes were assessed directly from infected tissue using a targeted sequencing approach. A total of 54 polymorphic sites were assessed in 93 infected plant samples revealing 28 unique multi-locus genotypes. Our results were consistent with previous studies indicating two clonal lineages are dispersed across both countries and the epidemiology is driven by clonal reproduction. Interestingly, the SNP markers revealed potentially functionally important, asexually-derived, genetic variation in nonsynonymous loci – including asexual variation in genes encoding RXLR effector proteins. This highlights the potential for rapid evolution within the context of clonal populations. The second pathogen, Peronospora farinosa f. sp. spinaciae is an obligate pathogen that causes downy mildew on spinach and is considered the most economically important disease of spinach. The objective of the current research was to assess genetic population structure of known historical races and isolates collected in 2014 from production fields in Yuma, Arizona and Salinas Valley, California were assessed using candidate synonymous SNPs identified by comparing sequence data from reference isolates of known races of the pathogen collected in 2009 and 2010. Genotypes were evaluated using targeted sequencing on genomic DNA extracted directly from infected plant tissue. Genotyping 26 historical and 167 modern samples at 46 SNP loci revealed 82 unique multi-locus genotypes. The unique genotypes clustered into six groups. The majority of isolates collected in 2014 were genetically similar, regardless of source location. The historical samples representing several of races showed greater genetic differentiation. Overall, the SNP data suggests within field genotypic variation was primarily a product of asexual development in production fields, whereas genetic diversity in the historical collection may be influenced by sexual recombination.

Published
2015

44. Identification of a Major QTL-Controlling Resistance to the Subtropical Race 4 of Fusarium oxysporum f. sp. cubense in Musa acuminata ssp. malaccensis

Author

Andrew Chen, Jiaman Sun, Guillaume Martin, Lesley-Ann Gray, Eva Hřibová, Pavla Christelová, Nabila Yahiaoui, Steve Rounsley, Rebecca Lyons, Jacqueline Batley, Ning Chen, Sharon Hamill, Subash K. Rai, Lachlan Coin, Brigitte Uwimana, Angelique D’Hont, Jaroslav Doležel, David Edwards, Rony Swennen, Elizabeth A. B. Aitken, Martin, Guillaume, Gray, Lesley A, Hribova, Eva, Christelova, Pavla, Yahiaoui, Nabila, Rounsley, Steve, Lyon, Rebecca, Batley, Jacqueline, Chen, Ning, Hamill, Sharon, Rai, Subash, Coin, Lachlan, Uwimana, Brigitte, D’Hont, Angelique, Dolezel, Jaroslav, Edwards, David, Swennen, Rony, and Aitken, Elizabeth AB

Subjects
Microbiology (medical), Infectious Diseases, General Immunology and Microbiology, Immunology and Allergy, Molecular Biology
Abstract

Vascular wilt caused by the ascomycete fungal pathogen Fusarium oxysporum f. sp. cubense (Foc) is a major constraint of banana production around the world. The virulent race, namely Tropical Race 4, can infect all Cavendish-type banana plants and is now widespread across the globe, causing devastating losses to global banana production. In this study, we characterized Foc Subtropical Race 4 (STR4) resistance in a wild banana relative which, through estimated genome size and ancestry analysis, was confirmed to be Musa acuminata ssp. malaccensis. Using a self-derived F2 population segregating for STR4 resistance, quantitative trait loci sequencing (QTL-seq) was performed on bulks consisting of resistant and susceptible individuals. Changes in SNP index between the bulks revealed a major QTL located on the distal end of the long arm of chromosome 3. Multiple resistance genes are present in this region. Identification of chromosome regions conferring resistance to Foc can facilitate marker assisted selection in breeding programs and paves the way towards identifying genes underpinning resistance. ispartof: Pathogens vol:12 issue:2 ispartof: location:Switzerland status: Published online

Published
2023

45. AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter.

Author

Griffiths GO, FitzGerald R, Jaki T, Corkhill A, Reynolds H, Ewings S, Condie S, Tilt E, Johnson L, Radford M, Simpson C, Saunders G, Yeats S, Mozgunov P, Tansley-Hancock O, Martin K, Downs N, Eberhart I, Martin JWB, Goncalves C, Song A, Fletcher T, Byrne K, Lalloo DG, Owen A, Jacobs M, Walker L, Lyon R, Woods C, Gibney J, Chiong J, Chandiwana N, Jacob S, Lamorde M, Orrell C, Pirmohamed M, and Khoo S

Subjects
Cohort Studies, Humans, SARS-CoV-2, Treatment Outcome, COVID-19, Pandemics
Abstract

Background: There is an urgent unmet clinical need for the identification of novel therapeutics for the treatment of COVID-19. A number of COVID-19 late phase trial platforms have been developed to investigate (often repurposed) drugs both in the UK and globally (e.g. RECOVERY led by the University of Oxford and SOLIDARITY led by WHO). There is a pressing need to investigate novel candidates within early phase trial platforms, from which promising candidates can feed into established later phase platforms. AGILE grew from a UK-wide collaboration to undertake early stage clinical evaluation of candidates for SARS-CoV-2 infection to accelerate national and global healthcare interventions., Methods/design: AGILE is a seamless phase I/IIa platform study to establish the optimum dose, determine the activity and safety of each candidate and recommend whether it should be evaluated further. Each candidate is evaluated in its own trial, either as an open label single arm healthy volunteer study or in patients, randomising between candidate and control usually in a 2:1 allocation in favour of the candidate. Each dose is assessed sequentially for safety usually in cohorts of 6 patients. Once a phase II dose has been identified, efficacy is assessed by seamlessly expanding into a larger cohort. AGILE is completely flexible in that the core design in the master protocol can be adapted for each candidate based on prior knowledge of the candidate (i.e. population, primary endpoint and sample size can be amended). This information is detailed in each candidate specific trial protocol of the master protocol., Discussion: Few approved treatments for COVID-19 are available such as dexamethasone, remdesivir and tocilizumab in hospitalised patients. The AGILE platform aims to rapidly identify new efficacious and safe treatments to help end the current global COVID-19 pandemic. We currently have three candidate specific trials within this platform study that are open to recruitment., Trial Registration: EudraCT Number: 2020-001860-27 14 March 2020 ClinicalTrials.gov Identifier: NCT04746183  19 February 2021 ISRCTN reference: 27106947., (© 2021. The Author(s).)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results